Rigel Pharmaceuticals (RIGL) Prepaid Assets (2010 - 2026)
Rigel Pharmaceuticals' quarterly Prepaid Assets came in at $25.7 million in Q1 2026, up 10.7% year-on-year from $23.3 million in Q1 2025, and up 394.45% quarter-over-quarter from $5.2 million in Q4 2025.
Rigel Pharmaceuticals has reported Prepaid Assets for 17 years, with the latest figure at $25.7 million in Q1 2026.
- For the quarter ending Q1 2026, Prepaid Assets rose 10.7% year-over-year to $25.7 million; the trailing twelve-month figure through Mar 2026 stood at $25.7 million (up 10.7% YoY), and the FY2025 full-year result was $5.2 million, up 15.12% from the prior year.
- Prepaid Assets for Q1 2026 stood at $25.7 million, up from $5.2 million in the prior quarter.
- The five-year high for Prepaid Assets was $25.7 million in Q1 2026, with the low at $3.0 million in Q3 2023.
- Average Prepaid Assets over 5 years is $9.7 million, with a median of $7.9 million recorded in 2022.
- Year-over-year, Prepaid Assets plunged 51.03% in 2023 and jumped 231.48% in 2024.
- Tracing RIGL's Prepaid Assets over 5 years: stood at $8.3 million in 2022, then decreased by 24.19% to $6.3 million in 2023, then declined by 27.76% to $4.5 million in 2024, then gained by 15.12% to $5.2 million in 2025, then surged by 394.45% to $25.7 million in 2026.
- The last three Prepaid Assets figures came in at $25.7 million (Q1 2026), $5.2 million (Q4 2025), and $18.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.75 Mn |
| Dec 31, 2025 | 5.21 Mn |
| Sep 30, 2025 | 18.56 Mn |
| Jun 30, 2025 | 5.44 Mn |
| Mar 31, 2025 | 23.26 Mn |
| Dec 31, 2024 | 4.52 Mn |
| Sep 30, 2024 | 9.99 Mn |
| Jun 30, 2024 | 8.66 Mn |
| Mar 31, 2024 | 8.85 Mn |
| Dec 31, 2023 | 6.26 Mn |
| Sep 30, 2023 | 3.02 Mn |
| Jun 30, 2023 | 4.97 Mn |
| Mar 31, 2023 | 7.87 Mn |
| Dec 31, 2022 | 8.26 Mn |
| Sep 30, 2022 | 6.16 Mn |
| Jun 30, 2022 | 7.94 Mn |
| Mar 31, 2022 | 9.42 Mn |
| Dec 31, 2021 | 7.41 Mn |
| Sep 30, 2021 | 5.93 Mn |
| Jun 30, 2021 | 6.61 Mn |
| Mar 31, 2021 | 8.27 Mn |
| Dec 31, 2020 | 14.05 Mn |
| Sep 30, 2020 | 10.36 Mn |
| Jun 30, 2020 | 7.18 Mn |
| Mar 31, 2020 | 9.12 Mn |
| Dec 31, 2019 | 9.46 Mn |
| Sep 30, 2019 | 5.79 Mn |
| Jun 30, 2019 | 3.97 Mn |
| Mar 31, 2019 | 4.65 Mn |
| Dec 31, 2018 | 3.48 Mn |
| Sep 30, 2018 | 1.56 Mn |
| Jun 30, 2018 | 1.55 Mn |
| Mar 31, 2018 | 2.32 Mn |
| Dec 31, 2017 | 1.68 Mn |
| Sep 30, 2017 | 1.49 Mn |
| Jun 30, 2017 | 1.49 Mn |
| Mar 31, 2017 | 1.38 Mn |
| Dec 31, 2016 | 1.45 Mn |
| Sep 30, 2016 | 1.29 Mn |
| Jun 30, 2016 | 1.86 Mn |
| Mar 31, 2016 | 1.78 Mn |
| Dec 31, 2015 | 2.55 Mn |
| Sep 30, 2015 | 1.67 Mn |
| Jun 30, 2015 | 1.23 Mn |
| Mar 31, 2015 | 1.26 Mn |
| Dec 31, 2014 | 1.63 Mn |
| Sep 30, 2014 | 1.27 Mn |
| Jun 30, 2014 | 1.51 Mn |
| Mar 31, 2014 | 2.44 Mn |
| Dec 31, 2013 | 2.35 Mn |
| Sep 30, 2013 | 2.13 Mn |
| Jun 30, 2013 | 2.94 Mn |
| Mar 31, 2013 | 2.96 Mn |
| Dec 31, 2012 | 4.22 Mn |
| Sep 30, 2012 | 2.73 Mn |
| Jun 30, 2012 | 3.73 Mn |
| Mar 31, 2012 | 2.78 Mn |
| Dec 31, 2011 | 2.59 Mn |
| Sep 30, 2011 | 2.91 Mn |
| Jun 30, 2011 | 3.47 Mn |
| Dec 31, 2010 | 2.63 Mn |